Reactive cutane-ous capillary endothelial proliferation
Conditions
Interventions
Treatment Group:Take itraconazole capsules orally
Sponsors
Affiliated Hospital of Guangdong Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients who developed reactive cutaneous capillary hyperplasia after treatment with camrelizumab for tumors; 2. Fully understand this trial and voluntarily sign the informed consent form; 3. The age of the male or female subjects was 18 years old; 4. The liver function of the subject was normal.
Exclusion criteria
Exclusion criteria: 1. The patient is a pregnant or lactating woman; 2. Currently participating in any research involving intervention measures outside of regular clinical practice; 3. Currently taking drugs that have drug interactions with itraconazole, such as midazolam, triazolam, simvastatin, digoxin, warfarin, cyclosporine, tacrolimus, as well as erythromycin and clarithromycin, etc; 4. The researchers judged other situations that were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of hemangiomas;The size of the hemangioma;The color of hemangioma; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse drug reactions; | — |
Countries
China
Contacts
Public ContactWu Wei
Affiliated Hospital of Guangdong Medical College
Outcome results
None listed